Thursday, April 7, 2022

Pfizer, BioNTech amp up COVID-19 vaccine dose target again—this time to 2.5B doses

Pfizer and BioNTech have hustled to produce as many COVID-19 vaccine doses as possible this year, and that effort keeps paying off. After jacking up their dose-delivery goal to 2 billion earlier this year, the companies are adding hundreds of millions of doses to their target.

The companies now aim to produce 2.5 billion doses of their Comirnaty vaccine in 2021, BioNTech said Tuesday. Manufacturing “optimization,” plus a recent factory approval in Marburg, Germany—and regulatory approvals for the six-dose vial—are driving the increase, the company said.

And this may not be the last boost to that goal. Pfizer and BioNTech are expanding their production and supplier network, and additional talks are underway.

Meanwhile, under vaccine purchase orders the partners have inked for 2021, BioNTech stands to collect around €9.8 billion, the company said Tuesday.

During a Reuters interview earlier this month, Pfizer CEO Albert Bourla, Ph.D., said the company would “clearly” exceed its supply goal of 2 billion doses. At the time, he projected the partners could make 2.3 billion to 2.4 billion doses. Previously, the companies had said they’d manufacture 1.3 billion doses by year-end.

Like other COVID-19 vaccine players, BioNTech and Pfizer are working 24/7 to produce as many doses of their authorized vaccine as possible. The other mRNA vaccine company with an authorized shot, Moderna, has said it’s working to produce up to 1 billion doses this year.

Beyond mRNA, Johnson & Johnson has said it’s targeting 1 billion doses of its adenovirus-based shot for 2021, while Novavax and AstraZeneca are eying multibillion-dose outputs this year.

RELATED: BioNTech nabs EU approval for former Novartis plant tapped in COVID-19 vaccine production push

As of last week, Pfizer and BioNTech had supplied more than 200 million doses of the vaccine globally. The partners have taken 2021 purchase orders of 1.4 billion doses, and talks are underway for more potential purchases.

BioNTech, which was a clinical-stage biotech before its shot scored emergency authorizations, also posted its first sales last year. The company pulled in €270.5 million after the shot’s December FDA authorization.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...